Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16002459 | 0.96 | MYC (0.34) | XDHMYCWDR5CTSSCTSK | |
| SCHEMBL2756419 | 0.92 | AR (0.39) | ARXDHMYCWDR5KDM1A | |
| SCHEMBL2756399 | 0.90 | AR (0.38) | ARXDHMYCWDR5KDM1A | |
| SCHEMBL16433981 | 0.89 | MYC (0.31) | MYCWDR5TDP2 | |
| SCHEMBL2756302 | 0.86 | AR (0.37) | ARXDHMYCWDR5KDM1A | |
| SCHEMBL2756306 | 0.86 | AR (0.37) | ARXDHMYCWDR5KDM1A | |
| SCHEMBL2756160 | 0.86 | KIF11 (0.41) | XDHMYCWDR5CTSSCTSK | |
| SCHEMBL16002454 | 0.84 | KIF11 (0.39) | XDHMYCWDR5CTSSCTSK | |
| SCHEMBL2756396 | 0.83 | AR (0.42) | ARXDHCTSSCTSKPDK2 | |
| SCHEMBL16002456 | 0.83 | ADORA1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088901-B2 | Azaindenofluorenedione derivative, material for organic electroluminescence device and organic electroluminescence device | IDEMITSU KOSAN CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20090315022-A1 | AZAINDENOFLUORENEDIONE DERIVATIVE, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANIC ELECTROLUMINESCENCE DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090315022-A1 | AZAINDENOFLUORENEDIONE DERIVATIVE, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANIC ELECTROLUMINESCENCE DEVICE | CYP19A1, HSD17B2, AZI2 | AR 164/4885XDH 1111/4885MYC 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.